Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry

Mar 27, 2025

1 min read

Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work.

https://vimeo.com/1070089995?share=copy

Recent Posts

See All

Zentalis aims to deliver to the ovarian cancer community a precision medicine approach - a targeted (WEE1) oral therapy for patients who are Cyclin E1 positive

BIO-Europe 2026: Bionyra Pharma emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab

$BIO-Europe 2026: Abalos Therapeutics will have p1 data on its lead project in 1H27, a non-oncolytic arenavirus-based product that is being tested in refractory/relapsed solid tumors$

BIO-Europe 2026: Abalos Therapeutics will have p1 data on its lead project in 1H27, a non-oncolytic arenavirus-based product that is being tested in refractory/relapsed solid tumors

Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight